Celiprolol and sympatho‐immune interface in <scp>COVID</scp>‐19-Reference-Cited by-同舟云学术

Celiprolol and sympatho‐immune interface in COVID‐19

Published:2023-09-07 Issue:4 Volume:170 Page:579-582
ISSN:0019-2805
Container-title:Immunology
language:en
Short-container-title:Immunology

Author:

Al‐Kuraishy Hayder M.¹,Albuhadily Ali K.¹,Al‐Gareeb Ali I.¹,El‐Bouseary Maisra M.²^ORCID,Alexiou Athanasios³⁴^ORCID,Papadakis Marios⁵,Batiha Gaber El‐Saber⁶

Affiliation:

1. Department of Clinical Pharmacology and Medicine College of Medicine, Al‐Mustansiriya University Baghdad Iraq

2. Department of Pharmaceutical Microbiology, Faculty of Pharmacy Tanta University Tanta Egypt

3. Department of Science and Engineering Novel Global Community Educational Foundation Hebersham New South Wales Australia

4. AFNP Med Wien Austria

5. Department of Surgery II University Hospital Witten‐Herdecke, University of Witten‐Herdecke Wuppertal Germany

6. Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine Damanhour University Damanhour AlBeheira Egypt

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/imm.13693

Reference26 articles.

1. Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity

2. Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19

3. The β2-subtype of adrenoceptors mediates inhibition of pro-fibrotic events in human lung fibroblasts

4. Bidirectional Role of β2-Adrenergic Receptor in Autoimmune Diseases

5. Beta 2 adrenergic receptor polymorphisms: association with factor VIII and von Willebrand factor levels and the risk of venous thrombosis